ABSTRACT The purpose of this study was to determine whether streptokinase (1) exacerbates intramyocardial hemorrhage during coronary reperfusion, (2) has any intrinsic effect on myocardial infarct size other than its ability to lyse proximal thrombi in coronary arteries, and (3) can abolish the no-reflow phenomenon. Anesthetized open-chest dogs underwent coronary occlusion for 3 hr followed by 3 hr of reperfusion. Area of infarct was assessed by tetrazolium staining, anatomic zone of no-reflow by injection of the fluorescent dye thioflavin S at the end of the reperfusion period, regional blood flow during occlusion and reperfusion by the radioactive microsphere technique, and extent of gross hemorrhage by assessment of photographic enlargements of the heart slices. Area of infarction of the left ventricle was similar in control ( 13.4 + 3.6%) and streptokinase-treated dogs ( 13.0 ± 2.9%; p = NS). Seven of eight dogs in the untreated group had anatomic perfusion defects as assessed by thioflavin S at the end of the reperfusion phase; seven of eight dogs in the streptokinase group had anatomic perfusion defects. There was no difference in the extent of gross hemorrhage between the two groups (6.5 ± 2. 1% of left ventricle in controls and 5.7 ± 2.3% in streptokinase-treated dogs). Severe depression of regional blood flow during reperfusion was present within the infarcted tissue and was associated with an anatomic perfusion defect as defined by thioflavin S; there was moderate depression of flow within the noninfarcted, salvaged subepicardium. In a separate series of experiments, infarcts were assessed for hemoglobin content. Intramyocardial hemoglobin levels were not higher after fibrinolytic therapy plus reperfusion compared with reperfusion alone. In conclusion, streptokinase did not exacerbate myocardial hemorrhage after coronary reperfusion, had no effect on infarct size, and did not abolish the no-reflow phenomenon. The no-reflow phenomenon is unlikely to be caused by fibrin thrombi. Circulation 70, No. 3, 513-521, 1984. OVER THE LAST 4 to 5 years there has been intense interest in the concept of treating patients with acute myocardial infarction with fibrinolytic therapy.'1 Several studies have shown that patients with acute myocardial infarction can safely undergo coronary angiography followed by intracoronary administration of streptokinase to lyse the intracoronary thrombus. Recent investigations show that intravenous streptokinase may also be effective.8 Approximately 80% to 85% of patients have successful thrombolysis with intracoronary streptokinase, which has been associated with amelioration of chest pain, improved electrocardiogra-
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To assess whether there were qualitative differences in the appearance of necrosis or the extent of hemorrhage in infarcts reperfused with streptokinase compared with untreated reperfused infarcts, an entire transverse midpapillary left ventricular slice from each dog was fixed in formalin. The slice was dissected to encompass the whole infarct, which was processed for histologic examination.
To better quantitate the degree of hemorrhage after coronary reperfusion, a separate group of anesthetized open-chest dogs (n = 14) was also subjected to 3 hr of proximal occlusion of the LAD followed by 3 hr of reperfusion. At 50 min of ischemia the dogs were randomly assigned to control or streptokinase treatment. The investigators were blinded as to the treatment regimen. At the end of 60 min of coronary occlusion, treated dogs received an intravenous bolus dose of streptokinase (10,714 IU/ kg infused over 30 min) followed by 1425 lU/kg/hr until death. Untreated dogs received an equivalent volume of saline. After 3 hr of reperfusion the heart was excised, cut into 5 mm transverse slices, and weighed. Two nonadjacent slices from the midpapillary region of the heart were placed aside for hemoglobin analysis. The remaining slices were incubated in TTC to visualize the zone of irreversible damage. The entire infarct from the slices used for hemoglobin analysis was dissected by using the opposite block faces of their adjacent slices as a guide to infarct location. The infarcted region of these two slices and remote noninfarcted tissue were then subjected to analysis of hemoglobin as previously described.2-27 An estimate of the extent of necrosis within the left ventricular slices used for hemoglobin analysis was determined by dividing the weight of the infarcted region by the total weight of the respective slice.
Differences in percent of hemorrhage and percent of necrosis in the left ventricle between the control and streptokinase groups were analyzed by Student's t test.
Results
Twenty-six dogs were entered into the study to assess the presence of an anatomic reperfusion defect, quantitate infarct size and hemorrhagic zone by gross analysis, and measure regional myocardial blood flow. Nine dogs were excluded because of ventricular fibrillation (VF); seven developed VF before randomization and two after. The two that had VF after randomization were both in the control group and both developed VF during reperfusion. One The gross qualitative appearance of the infarcts and hemorrhagic zones did not differ between control and streptokinase-treated dogs. The presence of an anatomic reperfusion defect was assessed by injection of thioflavin S dye just before the dog was killed, at a time when the coronary clamp was removed. Thioflavin S is known to stain endothelial cells fluorescent yellow-green when they are receiving flow'6; cells are not stained when flow is very low. The anatomic reperfusion defects appeared as nonfluorescent tissue when the slices were viewed under ultraviolet light (figures 2 and 4). Seven out of eight dogs in each group had anatomic reperfusion defects. These reperfusion defects were similar to those termed "noreflow phenomenon" in previous studies.'6 The anatomic reperfusion defects were also confined to the necrotic area and did not appear to extend beyond it. They corresponded to approximately the same areas as gross hemorrhage.
Quantitative analysis (table 1) . The percentage of the left ventricle that was infarcted was 13.4 ± 3.6% in control dogs and 13.0 + 2.9% in streptokinase-treated dogs (p = NS). The zone of gross hemorrhage was in general smaller than the necrotic zone and averaged 6.5 ± 2. 1% of the left ventricle in control dogs and 5.7 ± 2.3% of the left ventricle in streptokinase-treated nase). Blood flow in the midmyocardium was reduced to 0.24 + 0. 10 ml/min/g in the control group and to 0. 18 + 0.06 ml/min/g in the streptokinase-treated group (p = NS between groups). Blood flow in the subepicardium averaged 0.45 + 0. 19 ml/min/g in control animals and 0.41 + 0.13 ml/min/g in streptokinase-treated animals; again no difference between groups was present during the period of ischemia. groups was early neutrophil infiltration (figures 5 and 6). Margination of neutrophils was prominent as well as the presence of neutrophils within the walls of blood vessels. This early neutrophil infiltration is in contrast to the findings of a previous report in which this type of infiltrate was less prominent in reperfused infarcts by 72 hr after reperfusion. 25 Hemoglobin analysis. Fourteen additional dogs were entered into a study in which the hemoglobin content of the infarcts was assessed. Three dogs developed VF before randomization. One dog from the streptokinase-treated group failed to develop an infarct and was excluded from the study. Of the remaining 10 dogs, five were untreated and five received streptokinase.
The mean hemoglobin concentration in noninfarcted tissue was 10. 1 ± 1.7 mg/g wet weight in untreated animals and 8.9 ± 1.3 mg/g wet weight in streptokinase-treated animals (p = NS; 3.0() mg/ in streptokinase-treated animlals (p NS). Therefore there was no evidence that librinolytic therapy enhanced reperfusion hemiiorrhage; in tact, there was a trendl for hemoglobin levels to) be lower iln the streptokinase-treated group, althouigh this was not statistically significant.
Ihe average extent of infarction in these slices was 28.0 7.3% in control animals and 30.3 t 6.8%/c in streptokinase-treated animals (p = NS).
Discussion
The results of this study suggest that ( I ) streptokinase has no intrinsic effect on reducing myocardial infarct size, (2) streptokinase does not exacerbate hemorrhage during reperfusion, and (3) the no-reflow phenomenon is not likely to be caused by fibrin thronbi.
There have been several studies that have examined the effects of hemorrhage in myocardial infarction. There has been considerable debate as to the cause of the no-reflow phenomenon.'618 The results of this study suggest that thrombi may not be an important cause. The very high dose of streptokinase administered has been shown to lyse thrombi in humans, and it is therefore unlikely that thrombi per se contributed to the no-reflow phenomenon, since the perfusion defects were present in both control and streptokinase-treated dogs. It is much more likely that the no-reflow phenomenon, as defined by an anatomic perfusion defect, is related to microvascular damage within the zone of necrosis. 16 In fact, the zone of no reflow often correlated very closely with the zone of gross hemorrhage. It is also conceivable that the early neutrophilic response contributed to the no-reflow phenomenon by white cell plugging.
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In a previous study, the neutrophil response was reduced at 3 days of reperfusion compared with infarcts that had not been reperfused.29 It is likely that with reperfusion, neutrophil infiltrate peaks very early and then is diminished a few days later at the time it normally peaks in infarcts that have not been reperfused.
In this study there were areas of very low regional myocardial blood flow in the subendocardium and the midmyocardium after reperfusion; these were the same areas where the anatomic perfusion defects as defined by thioflavin S were noted. These areas have been associated with microvascular damage within frankly infarcted tissue and white blood cell plugs and previously have been referred to as the 'zone of no reflow." However, in this study there was also a rep erfusion abnormality that was prominent in the reperfused, previously ischemic subepicardium. In this situation, the depression of regional flow 3 hr after release of the coronary occlusion was not as marked as that in the inner layers of the heart and was associated with tissue that was salvaged by coronary reperfusion and in which the microvasculature was intact.`9 It is not clear whether this subepicardial reperfusion abnormality is caused by the same process as the subendocardial reperfusion abnormality associated with frank infarction. Flow during reperfusion in this subepicardial tissue was high enough to allow thioflavin S to penetrate the tissue but low enough that moderately reduced flow was detected by microspheres. Perhaps the reperfusion defect in this area should be referred to as "low reflow" rather than "no reflow.--In a previous study this phenomenon was 
